ライフサイエンスコーパス: photocoagulation

1 perative emesis and intraoperative extensive photocoagulation.

2 tcomes two months after treatment with laser photocoagulation.

3 t were subsequently treated with focal laser photocoagulation.

4 nctive cryotherapy, intracameral cautery, or photocoagulation.

5 larization and underwent prior thermal laser photocoagulation.

6 e identified HS was treated with focal laser photocoagulation.

7 in eyes that are nonresponsive to panretinal photocoagulation.

8 s were treated with ranibizumab plus scatter photocoagulation.

9 (71/407) of patients were eligible for laser photocoagulation.

10 ement or confirmation of complete panretinal photocoagulation.

11 us aflibercept vs vitrectomy with panretinal photocoagulation.

12 of other nonmedical treatments such as laser photocoagulation.

13 ithout a history of peripheral retinal laser photocoagulation.

14 favor of initial vitrectomy with panretinal photocoagulation.

15 IOP elevation in mice was achieved by laser photocoagulation.

16 urs, 3 days, 14 days, and 28 days post-laser photocoagulation.

17 itial monthly doses (2PRN), or macular laser photocoagulation.

18 scularization was treated with scatter laser photocoagulation.

19 e the kinetics of FAF recovery after retinal photocoagulation.

20 elevated in Wistar rats by translimbal laser photocoagulation.

21 therapeutic cellular response to focal laser photocoagulation.

22 sthetized cats underwent retinal argon laser photocoagulation.

23 erapy the only available treatment was laser photocoagulation.

24 e perifovea in one eye were ablated by laser photocoagulation.

25 CNV was induced in rats by laser photocoagulation.

26 nti-CD144, or control, before or after laser photocoagulation.

27 ls is to rupture Bruch's membrane with laser photocoagulation.

28 ents and fluorescein angiography after laser photocoagulation.

29 that drusen may resolve after macular laser photocoagulation.

30 sponds poorly to focal or grid-pattern laser photocoagulation.

31 patients, which was managed with panretinal photocoagulation.

32 fter 5 monthly doses (2q8), or macular laser photocoagulation.

33 in photodynamic therapy (vPDT); or (4) laser photocoagulation.

34 fter 5 monthly doses (2q8), or macular laser photocoagulation.

35 effectively treated with percutaneous laser photocoagulation.

36 ucose solution with dialysis and pan-retinal photocoagulation.

37 imited benefit of macular grid-pattern laser photocoagulation (1 citation).

38 participants) or vitrectomy with panretinal photocoagulation (105 participants).

39 (topical and/or systemic) or underwent laser photocoagulation (29%) and/or surgery (55.6%).

40 ser (41 cases, 6.0%), and prophylactic laser photocoagulation (33 cases, 4.8%).

41 in 8 patients included vitrectomy (1), laser photocoagulation (4), intravitreal bevacizumab (5), intr

42 thout PDR at baseline, (3) having panretinal photocoagulation, (4) experiencing vitreous hemorrhage,

43 tment (pre-PDT vs. PDT) included argon laser photocoagulation (42.1% vs. 0.4%), PDT (0% vs. 43.8%), t

44 laterally by repeated trabecular argon laser photocoagulation 5 days after intracameral injection of

45 Laser photocoagulation (532-nm wavelength, 200-mW power, 0.05-

46 available for the role of macular grid laser photocoagulation (7) and scatter peripheral laser surger

47 tinal ischemia, which was treated with laser photocoagulation after retinal reapplication.

48 ation is best managed by applying panretinal photocoagulation after the first appearance of iris neov

49 ents with newly diagnosed CSDME: focal laser photocoagulation alone (L), focal laser plus intravitrea

50 etic retinopathy (PDR) usually is panretinal photocoagulation, an inherently destructive treatment th

51 and a controlled, randomized trial of laser photocoagulation and aspirin treatment in diabetic retin

52 xpert specialists for consideration of laser photocoagulation and for echocardiography to evaluate si

53 ll mice at 24, 72, and 168 hours after laser photocoagulation and from unlasered eyes and were tested

54 he posterior eye are mostly treated by laser photocoagulation and multiple intraocular injections, pr

55 factor injections or posterior segment laser photocoagulation and no neodymium-doped yttrium aluminum

56 RVO-associated macular edema was grid laser photocoagulation and observation for central RVO-associa

57 n 25% (60/240) and 34% (80/236) in the laser photocoagulation and observation groups, respectively.

58 ded the site of laser injury within 1 day of photocoagulation and peaked at 3 days.

59 CNV lesions were generated using laser photocoagulation and quantified by imaging; T-lymphocyte

60 urrent treatment modalities, including laser photocoagulation and repeated intraocular injection of V

61 PPV associated with membrane peel, laser photocoagulation and silicone oil tamponade was performe

62 PPV associated with retinectomy, laser photocoagulation and silicone oil tamponade was performe

63 Laser photocoagulation and vitrectomy surgery, the standard in

64 nd 67145 (prophylaxis of retinal detachment, photocoagulation) and patients with an International Cla

65 nt findings, need for further surgery, laser photocoagulation, and anti-vascular endothelial growth f

66 fluid, no cardiovascular disease, no scatter photocoagulation, and male gender, whereas in sham-treat

67 , and 19% (39/208) in the aflibercept, laser photocoagulation, and observation groups, respectively (

68 (3%) participants in the aflibercept, laser photocoagulation, and observation groups.

69 onsteroidal inflammatory agents, argon laser photocoagulation, and photodynamic therapy have been eff

70 Photodynamic therapy, laser photocoagulation, and transpupillary thermotherapy may b

71 ons such as enucleation, radiotherapy, laser photocoagulation, and transpupillary thermotherapy or a

72 s with BRVO and 9 with CRVO received scatter photocoagulation, and with mean follow-up of 9 months (B

73 mbined with standard treatments (e.g., laser photocoagulation), anti-inflammatory agents, or other no

74 izumab, intravitreal triamcinolone and laser photocoagulation appear to transiently decrease macular

75 lial growth factor injections and panretinal photocoagulation are important to prevent neovascular gl

76 s administered every 6 weeks with focal/grid photocoagulation at investigator discretion after week 1

77 so received angiography-guided macular laser photocoagulation at month 1 and again every 3 months for

78 vea of the treated eye were ablated by laser photocoagulation at the start of the diffuser-rearing pe

79 , the Bruch's membrane was ruptured by laser photocoagulation at three sites in each eye.

80 neovascularization is not amenable to laser photocoagulation because this would cause a blinding cen

81 four (27%) of 127 eyes with complete scatter photocoagulation before undergoing PPV compared with 22

82 22 (48%) of 46 eyes with incomplete scatter photocoagulation before undergoing PPV demonstrated post

83 e modalities exist including stenting, laser photocoagulation, brachytherapy, and chemotherapy used s

84 ition, 14 pigmented rats were treated with 3 photocoagulation burns in their right eyes.

85 because both selective targeting and thermal photocoagulation can be realized.

86 Therapeutic retinal laser photocoagulation can damage the neurosensory retina and

87 Subthreshold micropulse retinal laser photocoagulation caused equivalent histologic changes fr

88 o determine whether carefully titrated laser photocoagulation combined with vitrectomy and gas tampon

89 with carefully titrated juxtapapillary laser photocoagulation combined with vitrectomy and gas tampon

90 al implant (DEX implant) combined with laser photocoagulation compared with laser alone for treatment

91 on studies unequivocally show the benefit of photocoagulation compared with observation in reducing t

92 ual acuity improvement, increased panretinal photocoagulation completion rates, and reduced recurrent

93 us hemorrhage from PDR precluding panretinal photocoagulation completion.

94 Panretinal photocoagulation could be initiated for failure or futil

95 different levels of energy using diode laser photocoagulation coupled with an intraocular laser probe

96 ry thermotherapy, proton beam therapy, laser photocoagulation, CyberKnife radiation, or photodynamic

97 er of macula thickness, application of focal photocoagulation) did not show a consistent trend in fav

98 cate carefully titrated juxtapapillary laser photocoagulation followed by vitrectomy with gas tampona

99 went carefully titrated juxtapapillary laser photocoagulation followed immediately by vitrectomy and

100 l anti-VEGF therapy is as effective as laser photocoagulation for achieving regression of acute ROP.

101 reatment for diabetic retinopathy; (3) laser photocoagulation for branch retinal vein obstruction; (4

102 and without angiography-guided macular laser photocoagulation for center-involving diabetic macular e

103 stria), 13 patients (13 eyes) underwent grid photocoagulation for diabetic maculopathy.

104 al interventions of the following: (1) laser photocoagulation for exudative macular degeneration; (2)

105 in Occlusion Study randomized trial of laser photocoagulation for macular edema and for the managemen

106 lycemic and blood pressure control and laser photocoagulation for neovascularization and clinically s

107 Grid-pattern laser photocoagulation for perfused macular edema did not show

108 Infants treated with laser photocoagulation for severe ROP should be monitored with

109 al choroidal neovascularization, while laser photocoagulation for the same entity confers a 4.4% impr

110 Anti-VEGF therapy is superior to laser photocoagulation for treatment of moderate to severe vis

111 panretinal photocoagulation (PRP) and focal photocoagulation (FP) compared with fundus photography.

112 ession was identified in the CNVM induced by photocoagulation from day 5 (16.2% +/- 6.8% of the lesio

113 After the first laser photocoagulation, GGA was administered twice a week.

114 eat and extend with angiography-guided laser photocoagulation (GILA; n = 60).

115 extend with angiography-GuIded macular LAser photocoagulation (GILA; n = 60).

116 cizumab (IVB), both combined with grid laser photocoagulation (GLP) for macular edema (ME) secondary

117 ith retinal sparing may be possible if focal photocoagulation, guided by an MRI map, is performed.

118 s study did not show that grid-pattern laser photocoagulation had a significant beneficial effect for

119 Although laser photocoagulation has been the standard treatment for DME

120 lial growth factor therapy and laser retinal photocoagulation, have limitations and are associated wi

121 53E (MBCU), and no prior panretinal or focal photocoagulation in at least one eye at baseline.

122 CNV was induced by laser photocoagulation in C57BL/6 and Cd59a(-/-) mice using an

123 CNV was induced by laser photocoagulation in C57BL/6 mice using an argon laser, a

124 CNV was induced by laser photocoagulation in C57BL/6 mice.

125 One week after krypton laser photocoagulation in C57BL/6J mice, 34 of 60 burns (57%)

126 (NPDR) that underwent navigated focal laser photocoagulation in DME and were followed at 3, 6, and 1

127 alized retinal changes following focal laser photocoagulation in DME treatment.

128 reduction in CRT at 24 weeks than grid laser photocoagulation in eyes with macular edema after BRVO.

129 eye and subthreshold 532-nm micropulse laser photocoagulation in their left eye.

130 d subthreshold 810-nm diode micropulse laser photocoagulation in their right eye and subthreshold 532

131 ts of intravitreal injection of TRO on laser photocoagulation-induced CNV lesions in rat eyes (15 exp

132 ibility of gene transduction targeted to the photocoagulation-induced CNVM was demonstrated using ret

133 Then, beta-gal expression in each photocoagulation-induced CNVM was examined by observing

134 ectomy alone without gas tamponade and laser photocoagulation is a safe and effective method for mana

135 nical trial results showing that pan retinal photocoagulation is an excellent treatment for PDR, peop

136 Demarcation laser photocoagulation is associated with less morbidity than

137 Laser photocoagulation is challenging, requiring exact localiz

138 a (DME) with vision loss after macular laser photocoagulation is clinically valuable.

139 a (DME) with vision loss after macular laser photocoagulation is clinically valuable.

140 Panretinal photocoagulation is designed to increase retinal PO2 by

141 neovascularization suggested that grid laser photocoagulation is not useful for the improvement of vi

142 Treatment for PDR, panretinal photocoagulation, is inherently destructive and has sign

143 ravitreal injection, focal laser, panretinal photocoagulation, laterality of procedure, ranibizumab,

144 bit retina were destroyed by selective laser photocoagulation, leaving retinal inner neurons (bipolar

145 cord intraretinal Po(2) profiles from healed photocoagulation lesions in anesthetized cats breathing

146 After 1 day, the intraretinal photocoagulation lesions were sharply demarcated, wherea

147 eated with intravitreal bevacizumab or laser photocoagulation (LPC) and untreated eyes.

148 One study suggests that laser photocoagulation may be useful in prophylactically treat

149 Subthreshold micropulse photocoagulation may decrease this risk by selective tis

150 avitreal anti-VEGF medication and panretinal photocoagulation may help to prevent additional vision l

151 ompt location and destruction of the worm by photocoagulation, may improve the vision of affected pat

152 requently as every 4 weeks, focal/grid laser photocoagulation (n = 240), or observation (n = 236).

153 sed ROP following bilateral panretinal laser photocoagulation (n = 37; median gestational age [GA] =

154 aocular pressure (IOP) was elevated by laser photocoagulation of episcleral and limbal veins.

155 retinal reattachment, and the time to laser photocoagulation of ischemic retina.

156 s induced unilaterally in CD-1 mice by laser photocoagulation of limbal and episcleral veins 270 degr

157 Laser photocoagulation of limbal and episcleral veins induces

158 s induced unilaterally in CD-1 mice by laser photocoagulation of limbal and episcleral veins.

159 Selective laser photocoagulation of retinal telangiectasia at the retina

160 high-pressure glaucoma was produced by laser photocoagulation of the anterior chamber angle in 38 eye

161 aterally in 13 NIH Black Swiss mice by laser photocoagulation of the limbus.

162 he time to retinal reapplication until laser photocoagulation of the nonperfusion areas could be perf

163 ous of rabbits and pigs (but not cats) after photocoagulation of the outer retina.

164 Multiple CNV lesions were induced by laser photocoagulation of the retina in Brown-Norway rats.

165 In more severe conditions, direct endolaser photocoagulation of the telangiectasia was required.

166 as induced unilaterally by translimbal laser photocoagulation of the trabecular meshwork in Sprague-D

167 rtension was induced in a rat model by laser photocoagulation of the trabecular meshwork.

168 del of glaucoma was used that involved laser photocoagulation of the trabecular meshwork.

169 We describe OCT-guided localization and photocoagulation of these invisible tumors with 1-year f

170 A rat model of glaucoma with laser photocoagulation of trabecular meshwork was used.

171 sion was introduced by rose Bengal and laser photocoagulation on chimeric mice that were reconstitute

172 g intravenous fluorescein angiography, laser photocoagulation, optical coherence tomography, ophthalm

173 acular edema, and the need for intervention (photocoagulation or anti-VEGF) over 18 years of follow-u

174 red with controls treated with macular laser photocoagulation or intravitreal corticosteroid.

175 Panretinal photocoagulation or intravitreous ranibizumab injections

176 ially managed with aflibercept or with laser photocoagulation or observation and given aflibercept on

177 libercept was required for eyes in the laser photocoagulation or observation groups that had decrease

178 t reportedly does not respond well to either photocoagulation or photodynamic therapy (PDT).

179 eiving either ranibizumab plus scatter laser photocoagulation or ranibizumab alone for an additional

180 e nata, aflibercept 2.0 mg bi-monthly, laser photocoagulation or sham.

181 m creatinine (>291.7 micromol/L), or retinal photocoagulation or vitrectomy (first composite outcome)

182 rotective against the need for retinal laser photocoagulation or vitrectomy.

183 steroids, intravitreal ganciclovir and laser photocoagulation or vitrectomy.

184 R, 3.27; P = .005), extensive intraoperative photocoagulation (OR, 4.94; P < .001), and emesis postop

185 l growth factor (VEGF) injection, panretinal photocoagulation, or both for retinal ischemia.

186 gs, including vitrectomy, cryotherapy, laser photocoagulation, or photodynamic therapy, were excluded

187 vely (P < .001) and extensive intraoperative photocoagulation (P < .001).

188 Laser photocoagulation parameters can be specified to avoid no

189 Unlike standard laser photocoagulation, photodynamic therapy can close choroid

190 ) and therapeutic interventions (argon laser photocoagulation, photodynamic therapy, intravitreal cor

191 iretinal membrane formation, number of laser photocoagulation procedures, and anti-VEGF treatments we

192 of this study was to determine whether laser photocoagulation produces a similar increase in photorec

193 Cryotherapy and photocoagulation provide excellent control of small tumo

194 b, sub-Tenon's triamcinolone, and panretinal photocoagulation (PRP) after cataract surgery (instead o

195 validity of self-report of prior panretinal photocoagulation (PRP) and focal photocoagulation (FP) c

196 tudy was to compare the effect of panretinal photocoagulation (PRP) associated with intravitreal conb

197 Panretinal photocoagulation (PRP) for proliferative diabetic retino

198 nopathy has been managed by panretinal laser photocoagulation (PRP) for the past 40 years.

199 Eyes without preexistent panretinal photocoagulation (PRP) had a higher risk to undergo supp

200 Pan retinal photocoagulation (PRP) has provided an effective treatme

201 ularization (NV) before and after panretinal photocoagulation (PRP) in eyes with treatment-naive prol

202 nal nonperfusion before and after panretinal photocoagulation (PRP) in treatment-naive eyes with prol

203 Panretinal photocoagulation (PRP) is the standard treatment for red

204 opathy (PDR) in eyes treated with panretinal photocoagulation (PRP) or ranibizumab.

205 inopathy (PDR) be considered for pan-retinal photocoagulation (PRP) treatment within 1 month of diagn

206 gnosed high-risk PDR treated with panretinal photocoagulation (PRP) using either argon green laser (4

207 aflibercept (IVA) injection with panretinal photocoagulation (PRP) versus early vitrectomy for diabe

208 Panretinal laser photocoagulation (PRP) was shown to be beneficial for ey

209 asonable treatment alternative to panretinal photocoagulation (PRP) when managing proliferative diabe

210 ts including PPV, injections, and panretinal photocoagulation (PRP), as well as visual acuity at base

211 on graded fundus photographs, (2) panretinal photocoagulation (PRP), or (3) pars plana vitrectomy (PP

212 omewhat disorganized, as in human panretinal photocoagulation (PRP).

213 hy (PDR), previously treated with panretinal photocoagulation (PRP).

214 betic retinopathy (PDR) following panretinal photocoagulation (PRP).

215 giography (OCTA) before and after panretinal photocoagulation (PRP).

216 Panretinal photocoagulation rates declined from 784/1000 treated ey

217 Panretinal photocoagulation rates did not significantly change amon

218 Panretinal photocoagulation rates in diabetic macular edema (DME) e

219 Laser photocoagulation remains a safe and effective therapy, b

220 Destruction of damaged retina by photocoagulation remains the primary treatment nearly 50

221 ression of neovascularization, scatter laser photocoagulation remains the standard of care to prevent

222 While focal laser photocoagulation remains the standard of care, a new wav

223 is offered, and if the tumor is small, laser photocoagulation, resection, or thermotherapy can be use

224 tion of microaneurysms following focal laser photocoagulation resulted in hyperreflective spots and c

225 roups based on outcome after confluent laser photocoagulation: retinal detachment or favorable outcom

226 n groups, respectively (aflibercept vs laser photocoagulation risk difference, -2% [95% CI, -9% to 5%

227 otoma correlating with the site of the laser photocoagulation scar, and subfoveal choroidal neovascul

228 Two photocoagulation sessions (2 weeks apart) were sufficien

229 Use of laser photocoagulation significantly declined for treatment of

230 and without angiography-guided macular laser photocoagulation significantly decreased the number of i

231 key eyes (n = 20), matrix placement of laser photocoagulation sites elicited CNV as a component of th

232 Overall, 65% of the photocoagulation sites in the squirrel monkey and 37% of

233 iffuse FVT that expanded beyond the original photocoagulation sites, accompanied by neovascular infil

234 The macular photocoagulation studies unequivocally show the benefit

235 a median absolute difference of 0.19 Macular Photocoagulation Study disc areas (DA) in total atrophy

236 The Macular Photocoagulation Study has received praise for its many

237 eovascularization by argon laser pan-retinal photocoagulation successfully managed IOP increase durin

238 oward eye-saving procedures, including laser photocoagulation, surgical removal of tumor, and techniq

239 The OCT-guided localization and photocoagulation technique is valuable in achieving prec

240 of 263 participants in a trial comparing two photocoagulation techniques for DME.

241 Laser photocoagulation then was applied to the trabecular mesh

242 There was a good uptake of laser photocoagulation therapy among patients affected by DR i

243 etinopathy, and assess the outcomes of laser photocoagulation therapy in a diabetic population in Cam

244 ents (a composite of requirement for retinal photocoagulation therapy or vitrectomy, development of p

245 thy of prematurity (ROP) compared with laser photocoagulation therapy.

246 th elevated IOP, induced by trabecular laser photocoagulation, there was a significant loss of Rbpms-

247 ucleation, radiotherapy, chemotherapy, laser photocoagulation, thermotherapy, and cryotherapy.

248 ved ophthalmic treatment (cryotherapy, laser photocoagulation, thermotherapy, or plaque radiation the

249 ved away from submacular surgery and macular photocoagulation to antivascular endothelial growth fact

250 The addition of scatter photocoagulation to ranibizumab PRN may reduce progressi

251 Here we use photocoagulation to selectively destroy photoreceptors i

252 eyes with severe nonperfusion received laser photocoagulation to the nonperfused retina; laser-treate

253 rior segment neovascularization, until laser photocoagulation to the reapplied retina could be perfor

254 Adding angiography-guided laser photocoagulation to this dosing algorithm did not signif

255 ter month 40 received scatter and grid laser photocoagulation to try to reduce the need for injection

256 chronic DME despite at least one focal laser photocoagulation treatment (nine eyes) received 4 L/min

257 omic outcomes in a subgroup of macular laser photocoagulation treatment control (hereafter laser cont

258 omic outcomes in a subgroup of macular laser photocoagulation treatment control (hereafter laser cont

259 substantial vision loss after macular laser photocoagulation treatment for DME.

260 substantial vision loss after macular laser photocoagulation treatment for DME.

261 Panretinal photocoagulation treatment patterns and clinical experie

262 irmed that the angle was closed by the laser photocoagulation treatment.

263 as evidenced by a greater number of macular photocoagulation treatments and less reduction in SD OCT

264 Panretinal photocoagulation treatments declined from 109 840 proced

265 The mean number of macular photocoagulation treatments in Cohorts 1, 2, 3, and 4 wa

266 thickness (CMT), and mean number of macular photocoagulation treatments over the 2-year study period

267 hly (n = 30), treat and extend without laser photocoagulation (TREX; n = 60), and treat and extend wi

268 30), TReat and EXtend without macular laser photocoagulation (TREX; n = 60), and treat and extend wi

269 2 maculae of seven squirrel monkeys by laser photocoagulation using optimized laser parameters (532 n

270 main outcome was incident DR requiring laser photocoagulation, vitrectomy, and/or antiangiogenic ther

271 sk, 0.83 [95% CI, 0.55-1.27; P = .79]; laser photocoagulation vs observation risk difference, -1% [95

272 Focal/grid laser photocoagulation was added after 6 months if DME persist

273 Focal/grid laser photocoagulation was administered in 41%, 64%, and 52%,

274 Laser photocoagulation was administered in 75 eyes (62.0%), ou

275 Laser photocoagulation was applied to the mouse fundus using a

276 Laser photocoagulation was performed at the slit lamp or durin

277 Laser photocoagulation was performed at the temporal side of t

278 Laser photocoagulation was performed in wild-type and knockout

279 Panretinal photocoagulation was shown to be beneficial for eyes wit

280 Slit-lamp laser photocoagulation was sufficient in half of the cases.

281 Pan-retinal photocoagulation was the most common type of RLT perform

282 Laser photocoagulation was then applied to the trabecular mesh

283 Laser photocoagulation was then applied to the trabecular mesh

284 Laser photocoagulation was used to induce CNV in C57BL/6J mice

285 Laser photocoagulation was used to induce CNV in wild-type C57

286 Laser photocoagulation was used to induce CNV in wild-type C57

287 Bruch's membrane rupture by laser photocoagulation was used to induce CNV.

288 Laser photocoagulation was used to induce CNVM in rats.

289 Translimbal laser photocoagulation was used to induce unilateral IOP eleva

290 Laser photocoagulation was used to produce unilateral experime

291 Laser photocoagulation was used to rupture Bruch's membrane in

292 In all treated patients, focal laser photocoagulation was used to treat leaking telangiectasi

293 ous injections of bevacizumab and panretinal photocoagulation were administered, the new vessels regr

294 ring treatment with an intravitreal agent or photocoagulation) were significantly higher (hazard rati

295 Endoscopic photocoagulation, while more technically challenging and

296 re treated in one institution by using laser photocoagulation with combined computed tomographic (CT)

297 He was successfully treated using laser photocoagulation with resolution of vitreous and pre-ret

298 ) (P = 0.001), failure to receive panretinal photocoagulation within 2 weeks of surgery (P = 0.003),

299 % CI, -4% to 13%) and of complete panretinal photocoagulation without vitrectomy by 16 weeks was 44%

300 After laser photocoagulation, WT mice showed significantly greater V

301 H and was associated with incomplete scatter photocoagulation, younger age, and phakia before PPV.